Are you willing and BCR/ABL?
Leading clinical laboratories from around the world are participating in our international BCR/ABL RT-QPCR standardization & harmonization project, "Are you willing and BCR/ABL?"

More than fifty participants have completed the survey, received test materials and, as of the end of July, thirty-four participants have sent back their data.  These laboratories will receive their laboratory's, our laboratory's, and the group's anonymized test results by August 2nd. It is not too late to take part in this important study. To learn more on how you can participate please contact: bcrablproject@invivoscribe.com

Personalized Medicine & IVS
Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), we provide worldwide access to state of the art personalized molecular testing to physicians and cancer centers, enabling doctors to determine optimal treatment for each individual patient.

Research & Biotechnology
Development & Partnering

Upcoming Meetings and Conferences

November 17-20, 2010
AMP 2010 Annual Meeting, San Jose, CA USA

December 4-7, 2010
52nd ASH Annual Meeting, Orlando, FL USA

View all Events

Invivoscribe announces collaboration with ATCC

Invivoscribe has entered into a comprehensive agreement with American Type Culture Collection (ATCC) to standardize controls.

View all Press Releases

Invivoscribe developing companion diagnostic products

Invivoscribe is committed to new regulatory requirements that include development of companion diagnostics for new therapeutic agents.  Our first companion diagnostic will identify FLT3 mutations in patients with acute myeloid leukemia. Contact us to learn more about our program for development of companion diagnostic products.